CryoStor® CS10

Animal component-free, defined cryopreservation medium with 10% DMSO
From: 245 USD


* Required Fields

Catalog # (Select a product)
Animal component-free, defined cryopreservation medium with 10% DMSO
From: 245 USD



CryoStor® CS10 is a uniquely formulated serum-free, animal component-free, and defined cryopreservation medium containing 10% dimethyl sulfoxide (DMSO). Designed to preserve cells in low temperature environments (-80°C to -196°C), CryoStor® CS10 provides a safe, protective environment for cells and tissues during the freezing, storage, and thawing processes. CryoStor® CS10 is recommended for the cryopreservation of hepatocytes, tissue samples, human peripheral blood, CHO cells, myeloma cell lines, hybridomas, human mesenchymal stem cells, human embryonic and human induced pluripotent stem cells (ES cells and iPS cells) and other extremely sensitive cell types. CryoStor® CS10 is cGMP-manufactured with USP grade components.
• Ready-to-use
• Serum-free, protein-free
• Animal component-free
• cGMP manufactured with USP grade / highest-quality components
• FDA master file
• Sterility, endotoxin, and cell-based quality control testing
• 10% dimethyl sulfoxide (DMSO)
• Other ingredients
Cell Type:
B Cells; CHO Cells; Hematopoietic Stem and Progenitor Cells; Hybridomas; Intestinal Cells; Macrophages; Mesenchymal Stem and Progenitor Cells; Monocytes; Myeloma; NK Cells; Other; Pluripotent Stem Cells; T Cells
Human; Mouse; Rat; Non-Human Primate; Other
Area of Interest:
Cord Blood Banking; Epithelial Cell Biology; Immunology; Stem Cell Biology
Animal Component-Free; Serum-Free; Defined

Technical Resources

Educational Materials


Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area Workflow Stages for
Workflow Stages

Data and Publications


Cell cycle (Georgetown, Tex.) 2016 JAN

Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions.

Slamecka J et al.


Amniotic fluid stem cells (AFSC) represent an attractive potential cell source for fetal and pediatric cell-based therapies. However, upgrading them to pluripotency confers refractoriness toward senescence, higher proliferation rate and unlimited differentiation potential. AFSC were observed to rapidly and efficiently reacquire pluripotency which together with their easy recovery makes them an attractive cell source for reprogramming. The reprogramming process as well as the resulting iPSC epigenome could potentially benefit from the unspecialized nature of AFSC. iPSC derived from AFSC also have potential in disease modeling, such as Down syndrome or -thalassemia. Previous experiments involving AFSC reprogramming have largely relied on integrative vector transgene delivery and undefined serum-containing, feeder-dependent culture. Here, we describe non-integrative oriP/EBNA-1 episomal plasmid-based reprogramming of AFSC into iPSC and culture in fully chemically defined xeno-free conditions represented by vitronectin coating and E8 medium, a system that we found uniquely suited for this purpose. The derived AF-iPSC lines uniformly expressed a set of pluripotency markers Oct3/4, Nanog, Sox2, SSEA-1, SSEA-4, TRA-1-60, TRA-1-81 in a pattern typical for human primed PSC. Additionally, the cells formed teratomas, and were deemed pluripotent by PluriTest, a global expression microarray-based in-silico pluripotency assay. However, we found that the PluriTest scores were borderline, indicating a unique pluripotent signature in the defined condition. In the light of potential future clinical translation of iPSC technology, non-integrating reprogramming and chemically defined culture are more acceptable.
Vox Sanguinis 2016 AUG

Relevance of flow cytometric enumeration of post-thaw leucocytes: influence of temperature during cell staining on viable cell recovery

Fritsch G et al.


Stem Cell Reviews and Reports 2016 AUG

Functionalizing Ascl1 with Novel Intracellular Protein Delivery Technology for Promoting Neuronal Differentiation of Human Induced Pluripotent Stem Cells

Robinson M et al.


Pluripotent stem cells can become any cell type found in the body. Accordingly, one of the major challenges when working with pluripotent stem cells is producing a highly homogenous population of differentiated cells, which can then be used for downstream applications such as cell therapies or drug screening. The transcription factor Ascl1 plays a key role in neural development and previous work has shown that Ascl1 overexpression using viral vectors can reprogram fibroblasts directly into neurons. Here we report on how a recombinant version of the Ascl1 protein functionalized with intracellular protein delivery technology (Ascl1-IPTD) can be used to rapidly differentiate human induced pluripotent stem cells (hiPSCs) into neurons. We first evaluated a range of Ascl1-IPTD concentrations to determine the most effective amount for generating neurons from hiPSCs cultured in serum free media. Next, we looked at the frequency of Ascl1-IPTD supplementation in the media on differentiation and found that one time supplementation is sufficient enough to trigger the neural differentiation process. Ascl1-IPTD was efficiently taken up by the hiPSCs and enabled rapid differentiation into TUJ1-positive and NeuN-positive populations with neuronal morphology after 8 days. After 12 days of culture, hiPSC-derived neurons produced by Ascl1-IPTD treatment exhibited greater neurite length and higher numbers of branch points compared to neurons derived using a standard neural progenitor differentiation protocol. This work validates Ascl1-IPTD as a powerful tool for engineering neural tissue from pluripotent stem cells.
Methods in molecular biology (Clifton, N.J.) 2016

Sendai Virus-Based Reprogramming of Mesenchymal Stromal/Stem Cells from Umbilical Cord Wharton's Jelly into Induced Pluripotent Stem Cells.

Miere C et al.


In an attempt to bring pluripotent stem cell biology closer to reaching its full potential, many groups have focused on improving reprogramming protocols over the past several years. The episomal modified Sendai virus-based vector has emerged as one of the most practical ones. Here we describe reprogramming of mesenchymal stromal/stem cells (MSC) derived from umbilical cord Wharton's Jelly into induced pluripotent stem cells (iPSC) using genome non-integrating Sendai virus-based vectors. The detailed protocols of iPSC colony cryopreservation (vitrification) and adaption to feeder-free culture conditions are also included.
Biopreservation and Biobanking 2015 JUN

Method Validation for Automated Isolation of Viable Peripheral Blood Mononuclear Cells

Hamot G et al.


Chat with an Expert